MBX Capital is a venture capital firm that focuses on "deep health," investing in early-stage biotech and health technology companies. Their strategy involves backing science-driven innovations that tackle the root causes of chronic illnesses, often linked to environmental factors, with the goal of achieving prevention and cures through therapeutics, platform technologies, and preventative solutions.
60% of their portfolio is in Healthcare. Their most common stage is seed (40% of deals). Average disclosed round size is $40.6M (across 5 rounds with reported amounts).
Portfolio
5
Fund Size
$100M
Top Stage
Seed
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
5 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Think Bioscience | Series A | $55M | Jan 2026 |
 Keebler Health | Seed | $6M | Feb 2025 |
 Vivodyne | Seed | $38M | Nov 2023 |
 Arine | Series B | $29M | Aug 2022 |
 ixlayer | Series A | $75M | Mar 2021 |
Top Co-Investors
Underdog Labs1 shared
Hustle Fund1 shared
New Stack1 shared
New Leaf Venture Partners1 shared
Katalyst Ventures1 shared
Innovation Endeavors1 shared
Janus Henderson Investors1 shared
YK Bioventures1 shared
AV8 Ventures1 shared
Buff Gold Ventures1 shared
General Catalyst1 shared
Uber1 shared
23andMe1 shared
Prologis1 shared
Khosla Ventures1 shared
Kairos1 shared
Last updated: 16 April 2026